They are sold on the same websites. They are stacked in the same protocols and discussed in the same forum threads. Chemically they have almost nothing in common.
The confusion matters, because the risks run the opposite way to how people rank them. SARMs get treated as the gentler option. They are also the category with a documented pattern of serious harm in young, previously healthy men.
If you have run these before and know all that already, skip ahead to what testing actually found inside the bottles. In a 2017 analysis, roughly half of products sold as SARMs contained no SARM.
Are SARMs peptides?
A peptide is a chain of amino acids
Short, built from the same units proteins are built from, and generally destroyed by digestion, which is why most are injected. Our guide on what peptides are covers the category properly.
A SARM is a small molecule
It binds the androgen receptor, the same receptor testosterone acts on. SARMs are not peptides, not proteins and not amino acid chains, and they belong chemically with drugs.
The word selective is the whole pitch. SARMs were designed to activate androgen receptors in muscle and bone while acting less on the tissues where testosterone causes the effects people want to avoid, because they are not converted to DHT by 5-alpha reductase or to oestrogen by aromatase.1
That design goal is real and it was pursued seriously. Several SARMs have been studied for sarcopenia, cancer cachexia and osteoporosis. None is approved.
Which compounds are which
The names are the practical problem, so here is the sorting.
Actual SARMs
Ostarine (MK-2866, enobosarm), ligandrol (LGD-4033), RAD-140 (testolone), andarine (S-4), YK-11 and S-23. All of them bind the androgen receptor.
Actual peptides
BPC-157, TB-500, the growth hormone secretagogues other than MK-677, and the GLP-1 drugs. All of them are chains of amino acids, and most are injected.
Neither
This is where the confusion concentrates. MK-677 or ibutamoren is a growth hormone secretagogue, and it is a small molecule rather than a peptide. Cardarine or GW501516 is a PPAR-delta agonist, covered below. SR9009 or stenabolic is a Rev-ErbA agonist. All three are routinely sold and discussed as SARMs and none of them is one.
If you are new to this, that third group is the one to learn. It is where the labelling is most often wrong, and it contains the compound with the most alarming safety history of anything on this page.
The three differences that matter
The receptor
A SARM acts on the androgen receptor, which is the system that governs testosterone. The growth hormone secretagogues act on a different axis entirely, and BPC-157 and the healing compounds act on neither. Everything else follows from that one difference.
The route
SARMs are oral. Most peptides are injected, for the digestion reason above. That practical difference is a large part of why SARMs feel less serious to people, and it says nothing about what happens once the compound is in you.
Suppression
Because SARMs act on the androgen receptor, they suppress your own testosterone production. Growth hormone secretagogues do not. Our guide on peptides under 25 covers why that difference matters most in the group where suppression is least advisable.
Do SARMs damage your liver?
The two categories separate here on evidence and not on theory.
Multiple independent peer-reviewed case reports describe drug-induced liver injury in young men taking RAD-140, one of the more popular SARMs.
A 24-year-old presented with jaundice and abdominal pain after five weeks of use, with a peak total bilirubin of 38.5 mg/dL, a cholestatic pattern, and a liver biopsy supporting the diagnosis. The formal causality assessment scored it as probable.2
A 22-year-old presented with jaundice, dark urine and pale stools after sixteen weeks, with total bilirubin around twenty-five times the upper limit of normal.3
A 29-year-old developed jaundice and raised enzymes after three months.4
The pattern across them is consistent. Previously healthy young men, weeks to months of use, a cholestatic injury, and resolution after stopping. That last part matters and it is not reassurance, because a bilirubin of 38 is a serious illness whether or not it resolves.
Why SARMs have case reports and peptides do not
The obvious conclusion is that SARMs are dangerous and peptides are safe. The evidence supports something narrower, and the reason is worth following.
Case reports exist when somebody takes a compound, gets ill in a recognisable way, and presents to a hospital that publishes. SARMs produce a specific, dramatic, attributable injury in a young person with no other explanation, which is the sort of thing that gets written up.
Most research peptides have no comparable literature. Our guide on why most peptides have no human evidence covers the reasons. Nobody is running trials, most compounds produce nothing acute enough to send a healthy person to hospital, and an absence of case reports is not a safety record.
So the accurate comparison is that one category has a documented harm and the other has an absence of information. Those are different things, and only one of them is reassuring.
Is what you bought actually a SARM?
This may matter more than the pharmacology, and it is unusually well documented.
In 2017, researchers bought 44 products sold online as SARMs and analysed them. Only 52% contained any SARM at all. Another 39% contained a different unapproved drug. A quarter contained substances not on the label, 9% contained no active compound whatsoever, and in 59% the amount present differed substantially from what was claimed.6
One of the other unapproved drugs found in products sold as SARMs was ibutamoren, which is MK-677. People buying a SARM were receiving a growth hormone secretagogue. The same confusion, occurring inside the bottle.
A European analysis published in 2024 found a comparable picture, which matters because the market has changed considerably in the intervening years. Of thirteen products bought from retail websites, 30% contained undeclared pharmaceuticals. Tamoxifen, clomifene, testosterone, tadalafil and an anabolic steroid were among them.7
Undeclared testosterone is the striking one. Somebody choosing a SARM specifically to avoid steroids may be taking a steroid.
So the liver case reports above describe people who took something labelled RAD-140. Whether they took RAD-140 is a separate question, and in roughly half of tested products the label was wrong.
Cardarine, which is not a SARM and is the sharpest example
GW501516 is sold as a SARM, discussed as a SARM, and stocked next to them. It is a PPAR-delta agonist, which means it acts on a receptor governing how the body uses fat for fuel, and it never touches the androgen receptor.
That misfiling matters because of what happened to it.
Cardarine was developed in the 1990s as a metabolic and cardiovascular drug candidate, and development was halted in 2007. The reason given consistently across the literature is that long-term animal studies linked it to tumour development in multiple organs.8 WADA later built a detection method for it and banned it in 2009.
One caveat on that, stated here rather than buried. We have not read the original toxicology at source. The abandonment and the WADA listing are well established; the specific tumour finding comes to us through secondary accounts, several of them commercial, and it deserves a primary citation it does not yet have.
A compound does not get dropped from a pipeline lightly. The people with the most complete picture of it decided it was not worth pursuing, and it has been sold online ever since under a category label that does not apply to it.
The one published human case involving it is not encouraging either. A 43-year-old sports coach presented to hospital with abdominal pain, muscle pain and severe headache after taking cardarine and ostarine together. ALT reached 922 and AST 2,558, with massive rhabdomyolysis and creatine kinase above 86,000. Both compounds were confirmed in his blood.9
That case is also the best illustration of the stacking problem described below, since two unrelated compounds were involved and only one of them is a SARM.
Are SARMs legal?
Both are unapproved. The FDA has issued public warnings about SARMs specifically, and they are widely sold under the same research-use framing our legality guide describes.5
In tested sport, both are prohibited. SARMs appear on the WADA list by name, peptides are caught by the category and the non-approved substances provision, and our guide on drug-tested sport covers what a violation actually costs.
Anybody telling you a SARM is the legal alternative to something is describing a marketing position, not a legal one.
How long does SARM suppression last?
Suppression is the easy half of that fact. How long it lasts is the part people actually need.
Recovery generally happens, and how long it takes varies with the compound, the dose and how long it ran. Weeks for a short course, longer for a long one, and it is not guaranteed to return fully in everybody.
Post-cycle therapy protocols circulate widely for exactly this. They typically use prescription drugs including tamoxifen and clomifene, obtained without a prescription, on schedules that have not been trialled for this purpose. Those are real drugs with real effects, taken by people self-treating a problem they created, and the protocols are no better evidenced than anything else in this space.
A blood test answers this and a forum does not. Testosterone, LH and FSH is an ordinary panel, and our bloodwork guide covers what a baseline is for. If yours has not recovered months after stopping, that is a conversation with a doctor rather than something to manage yourself.
Are SARMs safer than steroids?
The claim deserves a proper answer, and the evidence supports one.
They do appear to avoid some specific steroid harms. Not being converted to DHT or to oestrogen means less of the hair loss, prostate effects and gynaecomastia that drive people away from anabolic steroids, and that was the design goal.
The two that matter most are not avoided, starting with suppression of your own testosterone, which happens with both. And liver injury, which is the classic harm of oral anabolic steroids, is documented for SARMs in the case reports above.
So the claim is partly true and much narrower than it sounds. Safer in the ways you would notice, comparable in the ways you would not.
Stacking SARMs and peptides together
None of this stays theoretical, because people do not buy one or the other.
MK-677 in particular sits on the boundary. It is a growth hormone secretagogue, not a SARM and not a peptide, and it is sold alongside both. A protocol containing MK-677, RAD-140 and BPC-157 draws from three chemically unrelated categories with three different risk profiles and one shared characteristic, which is that none of them is approved.
Our guide on running more than one compound covers what that does to your ability to attribute anything. The short version is that if something goes wrong on a stack containing a SARM, the SARM is where a clinician will look first, and they will be right to.
What to take from this
Separate them when you are reading
A forum thread that treats them as interchangeable is not a source, whatever else it says.
Check your liver if you have taken a SARM
ALT, AST, ALP and bilirubin are a standard panel and any doctor can order it. Our bloodwork guide covers the approach, and jaundice, dark urine, pale stools or unexplained itching are the symptoms that make it urgent rather than routine.
Do not assume the injectable one is riskier
The route tells you about convenience, not about consequence.
If you are under 25
The suppression question applies specifically to you, for reasons our guide on that age group sets out.
What to do if you are taking one now
Most of this reads as reasons not to, which is little use if you are eight weeks in.
Get a liver panel
ALT, AST, ALP and bilirubin. Any doctor can order it, and asking is reason enough. Our guide on telling your doctor covers the conversation if you would rather not explain.
Know the symptoms that mean stop today
Jaundice, yellowing of the eyes, dark urine, pale stools, persistent itching or right upper abdominal pain. Those are not wait-and-see symptoms, and in the published cases they appeared anywhere from five weeks to four months in.
Stopping reversed it in every reported case
Every case above resolved after the compound was discontinued. That is not permission to carry on and it is the reason not to wait.
Get your testosterone checked afterwards
Not during, and give it some weeks before concluding anything.
Know what you actually took, if you can
You probably cannot. If the product came from a website with no batch testing, the label is roughly a coin flip.
Where this stops being useful
Whether any specific SARM is safe, which no trial has established for any of them.
Your own liver, which needs a blood test and not a website.
Anything about dosing for either category, which you will not find here.
Common questions
Are SARMs peptides?
No. A peptide is a chain of amino acids. A SARM is a small molecule that binds the androgen receptor, which is the same receptor testosterone acts on. They are chemically unrelated and sold together.
Are SARMs safer than steroids?
That was the design goal. The evidence does not settle it. SARMs avoid conversion to DHT and oestrogen, and multiple case reports describe serious liver injury in young men taking RAD-140.
Do SARMs suppress testosterone?
Yes. They act on the androgen receptor, which suppresses your own production, and growth hormone secretagogues do not work that way.
Which is riskier, a SARM or a peptide?
SARMs have a documented pattern of liver injury in the medical literature. Most research peptides have no literature at all, which is an absence of information rather than a safety record. Those are different things.
Is MK-677 a SARM?
No. It is a growth hormone secretagogue and not a peptide either, grouped with SARMs because it sits beside them on the same websites.
Are SARMs legal?
They are unapproved, the FDA has issued public warnings about them, and they are sold under the same research-use framing as peptides. They are also prohibited in tested sport by name.
I have been taking a SARM. Should I do anything?
A liver panel covering ALT, AST, ALP and bilirubin is a reasonable check, and any doctor can order it. Jaundice, dark urine, pale stools or unexplained itching make it urgent.
Is what I bought actually a SARM?
In a 2017 analysis of 44 products sold online as SARMs, only 52% contained any SARM. Another 39% contained a different unapproved drug, 9% contained no active compound, and 59% had amounts that did not match the label.
How long does suppression take to recover?
It varies with the compound, dose and duration, generally weeks to months, and it is not guaranteed to be complete. A testosterone, LH and FSH panel gives you an actual answer, and post-cycle protocols use prescription drugs on schedules nobody has trialled.
What symptoms mean I should stop now?
Jaundice, yellow eyes, dark urine, pale stools, persistent itching or right upper abdominal pain. In the published cases these appeared between five weeks and four months into use, and all resolved after stopping.
Can I stack them?
People do. It draws from unrelated categories with different risk profiles. It also removes any ability to work out what caused what if something goes wrong.
Sources
- Mechanism and design rationale of selective androgen receptor modulators. Described consistently across the peer-reviewed case report literature cited below. SARMs bind androgen receptors with tissue selectivity, promoting anabolic effects on muscle and bone while avoiding conversion to dihydrotestosterone by 5-alpha reductase and to oestrogen by aromatase, which is the basis of the reduced-androgenic-effect claim. Several have been investigated for sarcopenia, cancer cachexia, prostate and breast cancer, and osteoporosis. None is FDA approved. This description is currently assembled from the introductions of the case reports cited below, which is borrowed framing rather than a source. A pharmacology review should be cited directly before publication. ↩
- RAD-140 Drug-Induced Liver Injury. Ochsner Journal, 2022. Peer-reviewed case report, abstract read at source. A 24-year-old man presented with two weeks of diffuse abdominal pain, scleral icterus, pruritus and jaundice after five weeks of RAD-140. Cholestatic pattern of liver injury with a peak total bilirubin of 38.5 mg/dL. Liver biopsy showed intracytoplasmic and canalicular cholestasis with minimal portal inflammation. Drug-Induced Liver Injury Network causality score of 1, probable. Symptoms and injury resolved after cessation. The authors note that RAD-140 and other SARMs should be used judiciously and under close clinical supervision until further hepatic safety data become available. ↩
- Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature. Peer-reviewed case report, abstract read at source. A 22-year-old previously healthy man presented with two weeks of worsening jaundice, nausea, fatigue, pruritus, dark urine and pale stools after sixteen weeks of RAD-140. Total bilirubin 427.5 µmol/L, direct bilirubin 294 µmol/L, ALP 5.3 µkat/L. Viral hepatitis and autoimmune panels unremarkable. Note that the patient was also taking a separate performance supplement, which the report records and which complicates attribution. ↩
- Selective Androgen Receptor Modulators Leading to Liver Injury: A Case Report. Peer-reviewed case report, abstract read at source. A 29-year-old man developed jaundice and elevated liver enzymes after three months of RAD-140. Liver ultrasound showed hepatic steatosis and a hyperechoic lesion. Symptoms resolved after discontinuation. The authors state that causation cannot be proven in an individual case, and that the timing combined with the patient's prior health made RAD-140 the probable cause. ↩
- FDA public warning regarding SARMs, and WADA prohibited status. Referenced in the case report literature, which records that SARMs remain readily accessible online despite an FDA warning and a WADA ban, and are used as alternatives to anabolic-androgenic steroids. The FDA statement and the current WADA Prohibited List should both be cited directly before publication. See also our guide on drug-tested sport, which covers the sanction structure. ↩
- Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA 2017;318(20):2004-2010. Peer-reviewed chemical analysis, abstract and results read at source. 44 products available for purchase were identified from more than 210 found by search and analysed using WADA-approved procedures. Only 23 (52%) contained one or more SARMs, being ostarine, LGD-4033 or andarine. A further 17 (39%) contained another unapproved drug, including the growth hormone secretagogue ibutamoren, the PPAR-δ agonist GW501516 and the Rev-ErbA agonist SR9009. No active compound was detected in 4 (9%), substances not listed on the label were found in 11 (25%), and the amount differed substantially from the label in 26 of 44 (59%). None of five products from one supplier contained the compounds listed. The authors state the findings apply only to the products purchased and should not be treated as representative of all products. The study is from 2017 and the market has changed; a more recent equivalent would be worth citing alongside it. ↩
- Illegal products containing selective androgen receptor modulators purchased online from Italy: health risks for consumers. Peer-reviewed analysis, abstract read at source. Thirteen SARM products purchased from retail websites accessible from Italy, analysed by mass spectrometry and quantitative NMR. The stated SARM was confirmed in about 70% of samples. In 23% a different SARM was found instead, and in one sample no SARM was detected. Undeclared pharmaceutical substances including tamoxifen, clomifene, testosterone, epimethandienone and tadalafil were measured in 30% of samples. The authors also record that websites stated "for research only" while simultaneously giving dosage and training-phase instructions. Thirteen products is a small sample and the body text does not present the percentages as generalisable. ↩
- Development and abandonment of GW501516 (cardarine). Reported consistently across secondary sources. Developed from the 1990s as a candidate treatment for metabolic and cardiovascular disease, with development halted in 2007 after long-term animal studies linked it to the development of tumours in multiple organs in mice and rats. WADA developed a detection method and added it to the prohibited list in 2009. Every source consulted is secondary and several are commercial. The body text says so explicitly rather than leaving it in this note, because the cancer signal is the most alarming claim on the page. If the original toxicology cannot be located, the claim should be reduced to what is verifiable: that development was halted in 2007 and that WADA banned the compound in 2009. ↩
- Kintz P, Gheddar L, Paradis C, et al. Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR-δ) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine). Toxics 2021;9(10):251. doi:10.3390/toxics9100251. Peer-reviewed case report, abstract read at source. A 43-year-old male sports coach presented to an emergency unit with epigastric pain, myalgia and severe headache after some days of using cardarine and ostarine in combination. Cytolysis with ALT up to 922 UI/L and AST up to 2,558 UI/L, and massive rhabdomyolysis with creatine phosphokinase up to 86,435 UI/L. Cardarine and ostarine were confirmed in blood at 403 and 1 ng/mL respectively by LC-MS/MS. A single case involving two compounds taken together, so neither can be isolated as the cause, which is the point made in the body text about stacking. ↩